Indian pharma wants compulsory license on AZ's Onglyza; Novo pulls out of GLP-1 patch deal;

@FiercePharma: USDA amends rules to allow vets to make custom vaccines in their offices. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: Don't miss our July 8 Twitter chat on sustained release with BASF expert Thorsten Cech. Details are here | Follow @EricPFierce

@CarlyHFierce: ICYMI from FiercePharmaMarketing: Bayer draws up big sales plans for ex-Merck OTC meds. Story | Follow @CarlyHFierce

> A little-known Indian pharma company asked the country's patent office for a compulsory license on AstraZeneca's ($AZN) diabetes med Onglyza, which would force low-cost copycats onto the domestic market. Report

> Novo Nordisk ($NVO) pulled out of a collaboration with Zosano Pharma, which had been working on a patch version of GLP-1 diabetes treatment. Report

> Boehringer Ingelheim's cancer med Giotrif beat Roche's ($RHHBY) Tarceva in a head-to-head trial in previously treated patient with squamous lung cancer. Report

> European biotech companies are turning to U.S. markets to list their shares, finding stateside listings more lucrative. Report

> Japanese drugmaker Astellas was taken to task by U.K. drug-promotion watchdogs for an event promoting the prostate cancer drug Xtandi. Report

Medical Device News

@FierceMedDev: ICYMI: Quest and Quintiles rev up new lab testing JV. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Greek referendum: Next big deadline is payment to ECB (assuming no bank run). Sad & ironic that technocrats still have to make this decision. | Follow @VarunSaxena2

@EmilyWFierce: A Perfect Blood Test For Pancreatic Cancer? Forbes story | Follow @EmilyWFierce

> Report: Despite growth in the device industry, effective concussion treatment remains elusive. More

> Allergan to buy dry eye device startup Oculeve for $125M+. News

Biotech News

@FierceBiotech: Analyst Schoenebaum offers best-case scenario for Axovant's 4-time Alzheimer's loser. More | Follow @FierceBiotech

@JohnCFierce: The dog that didn't bark? Odd that $AXON trolls haven't been on my tail. Where are the die-hard fanatics? Is this mostly an insiders' game? | Follow @JohnCFierce

> 23andMe raises $79M as it ramps up R&D work. Item

> Novo Nordisk backs out of a diabetes deal with Zosano. Story

> Versartis gets out from under the FDA with its growth hormone treatment. Article

Pharma Marketing News

> Hot summer ad wars: Celgene launches Otezla DTC into crowded psoriasis drug market. More

> Sanofi, Regeneron break out the popcorn for cholesterol-fighting, PCSK9-friendly documentary. Story

> Expecting payer pushback, Vertex to field new CF med Orkambi at $259K. Article

> Dry-eye expert Allergan bets $125M on Oculeve and its new implant approach. Item

> Hotel workers lobby to stop Big Pharma funding for CME. More

Animal Health News

> Flu season over? Not for dogs. Item

> Patterson offloads medical unit to private equity firm for $715M, boosts focus on animal health. Report

> Report: With Valeant takeover rumors fading, could Zoetis buy IDEXX? More

> USDA amends rules to allow vets to make custom vaccines in their offices. Story

> FDA, Gates Foundation call for improved global access to veterinary drugs. Article

Biotech IT News

> Broad Institute snaps up GemCode Platform as 10X Genomics starts shipping. News

> Novartis steps into wearables with app for Apple Watch, Android Wear. More

> Mousera bags $20M VC round to advance sensor tech in preclinical research. Story

> BioClinica mounts European expansion to push imaging and eClinical. Article

> Congressman pushes to unshackle pharma on social media. Report

And Finally... A contraception campaign in Colorado has driven down the number of teen pregnancies dramatically. Report

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.